Accessibility Menu
Quantum BioPharma Ltd. logo

Quantum BioPharma Ltd.(OTC) QNTM

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-100%
5 Year-97%
1 Year-81%
1 Month+10%
N/A
Quantum BioPharma Ltd. last closing stock price
MetricPriceDate
Last closeUSD 3.172026-08-31
Quantum BioPharma Ltd. stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.16%USD 3.242026-08-24
1 month+9.69%USD 2.892026-07-31
3 month-37.96%USD 5.112026-06-02
Year to date-56.58%USD 7.302025-12-31
1 year-81.19%USD 16.852025-08-29
3 year-96.19%USD 83.212023-09-01
5 year-97.28%USD 116.352021-09-01
Since inception-99.72%USD 1,089.632018-06-11

Quantum BioPharma Ltd. Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$24.89M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Nov 6, 2026

QNTM News

Smoldering Fire Cannabis Bud Marijuana Weed Pot Canada US Getty

Canna-Bust! These 6 Pot Stocks Lost at Least 25% in July

Sean WilliamsAug 6, 2019
Cash Money Bills On Fire Invest Loss Bankrupt Getty

The 6 Worst Pot Stocks in the First Half of 2019

Sean WilliamsJul 2, 2019
Marijuana Plant Cannabis Pot Weed Legalization Getty

These 5 Pot Stocks Lost at Least 15% in the First Quarter

Sean WilliamsApr 9, 2019
Stock Trader Losing Money Investment Growth Value Getty

These 5 Pot Stocks Lost 16% (or More) in February

Sean WilliamsMar 5, 2019

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Quantum BioPharma Ltd.

Quantum BioPharma Ltd. is a biopharmaceutical company based in Toronto, Canada, focused on developing innovative solutions for complex neurodegenerative, inflammatory, and metabolic conditions. The company is advancing a diverse pipeline of drug candidates, including its flagship asset, Lucid-MS, which is currently in Phase 2 clinical trials.

Products and Services
  • Lucid-MS: A proprietary chemical entity targeting multiple sclerosis
  • Therapeutic solutions for alcohol addiction in clinical settings
  • Strategic investment holdings in residential real estate
Growth Outlook
  • Pipeline includes promising candidates addressing significant medical needs
  • Phase 2 trials for Lucid-MS could lead to pivotal advancements
  • Strategic investments may enhance financial stability and growth
Financial Highlights
  • Recent quarterly net income of -$3.17 million reflects ongoing R&D investments
  • Cash and short-term investments totaled $9.73 million as of June 30, 2026
  • Current ratio of 1.20 indicates adequate short-term financial health
Quantum BioPharma Ltd. is positioned in the biotechnology sector, focusing on innovative treatments for challenging health conditions. The company’s flagship product, Lucid-MS, aims to address the underlying causes of multiple sclerosis, with preclinical data suggesting its potential effectiveness. Additionally, the development of therapeutic solutions for alcohol addiction highlights the company's commitment to addressing pressing health issues. The growth outlook for Quantum BioPharma is bolstered by its diverse pipeline and ongoing clinical trials. The Phase 2 trials for Lucid-MS are particularly significant, as successful outcomes could lead to further advancements and potential market opportunities. Furthermore, the company's strategic investments in residential real estate may provide additional financial support, enhancing overall stability. Financially, Quantum BioPharma has shown resilience despite recent losses, with a focus on research and development. The company reported a net income loss of $3.17 million in the latest quarter, reflecting its commitment to advancing its drug candidates. With a current ratio of 1.20, Quantum BioPharma maintains a solid position to meet its short-term obligations, while its cash and short-term investments of $9.73 million provide a buffer for ongoing operations. Overall, Quantum BioPharma Ltd. presents a compelling opportunity for investors interested in the biotechnology sector, particularly those focused on innovative treatments for complex health conditions.
AI Generated • Aug 23, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

7

CEO

Zeeshan Saeed

Website

www.quantumbiopharma.com

Headquarters

Toronto, ON M5C 2V9, CA

QNTM Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-413.07%

Return on Capital

-174.19%

Return on Assets

-173.14%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-$250.78K

Operating Income

-$1.91M

EBITDA

-$23.66M

Operating Cash Flow

-$5.42M

Capital Expenditure

-$6.00

Free Cash Flow

-$5.42M

Cash & ST Invst.

$9.73M

Total Debt

$962.16K

Quantum BioPharma Ltd. Performance Analysis

Quantum BioPharma Ltd. annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Quantum BioPharma Ltd. sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Quantum BioPharma Ltd. annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.61-39.6%
20232023-12-31USD -0.46-24.4%
20242024-12-31USD -12.492612.8%
20252025-12-31USD -7.97-36.2%
Quantum BioPharma Ltd. sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3054.2%
Q42025-12-3143.6%
Q12026-03-31-277.2%
Q22026-06-3083.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$125.11K

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

17

N/A

Net Income

-$3.17M

+65.7%

EBITDA

-$2.12M

+77.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$9.73M

+536.9%

Total Debt

$962.16K

-57.5%

Accounts Receivable

$107.50K

-96.7%

Inventory

$52.95K

-31.1%

Long Term Debt

$0.00

N/A

Short Term Debt

$962.16K

-57.5%

Return on Assets

-1.73%

N/A

Return on Invested Capital

-31.43%

N/A

Free Cash Flow

-$1.74M

+10.5%

Operating Cash Flow

-$1.74M

+10.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RVPHReviva Pharmaceuticals Holdings, Inc.
$0.48-7.43%
ANVSAnnovis Bio, Inc.
$1.72+0.00%
CPIXCumberland Pharmaceuticals Inc.
$6.69-20.92%
PYPDPolyPid Ltd.
$5.14+1.38%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About QNTM

What is the current price of Quantum BioPharma Ltd.?

Quantum BioPharma Ltd. is trading at N/A per share.

What is the 52-week range for Quantum BioPharma Ltd.?

Over the past 52 weeks, Quantum BioPharma Ltd. has traded between N/A and N/A.

How much debt does Quantum BioPharma Ltd. have?

As of the most recent reporting period, Quantum BioPharma Ltd. reported total debt of $963.31K.

How much cash does Quantum BioPharma Ltd. have on hand?

Quantum BioPharma Ltd. reported $3.65M in cash and cash equivalents in its most recent financial results.

What is Quantum BioPharma Ltd.’s dividend yield?

Quantum BioPharma Ltd. does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services